Loading organizations...
Key people at Brookline Capital Markets.
Brookline Capital Markets is a New York investment banking and advisory firm specializing in the life sciences, medical technology, and diagnostics sectors. Operating through Arcadia Securities, the organization provides comprehensive services including initial public offerings, follow-on offerings, and private investments in public equity for emerging growth healthcare enterprises. The firm employs approximately 33 people, generates an estimated $6 million in annual revenue, and has successfully completed over 300 capital markets transactions as a bookrunner, co-manager, or advisor. Key personnel include Managing Partner Michael Fontaine and Senior Scientific Advisor Samuel Wertheimer, while the executive leadership team draws on prior experience from institutions such as Lazard Capital Markets. The company was founded in 2013 by William Buchanan, Scott Katzmann, and Harris Lydon to source capital from institutional investors and a proprietary network of family offices and individuals.
Key people at Brookline Capital Markets.
Brookline Capital Markets is a boutique investment bank specializing in capital markets and advisory services for life sciences, medical technology, diagnostics companies, SPACs, and emerging growth enterprises.[1][3][4] Its mission centers on delivering full-suite financing solutions—from private placements to IPOs—sourcing capital from institutional investors and a proprietary network of global family offices and high-net-worth individuals, with a track record of over 200 transactions valued at $6.4 billion.[1][2] The firm's investment philosophy emphasizes long-term client partnerships, repeat business (with repeat clients driving much of its private capital raises exceeding $400 million), and deep sector expertise to support companies from inception to public markets.[1][3]
Brookline's key sectors are healthcare-focused, particularly pre-IPO life sciences and medtech, where it has built a market-leading platform; it also produces the monthly Brookline Brief to analyze equity capital markets trends in these areas.[1][2][5] In the startup ecosystem, it significantly impacts emerging healthcare ventures by providing strategic advice, private capital (e.g., convertible notes and preferred stock via 30+ transactions), and public market execution as bookrunner or placement agent, fostering growth and longevity for clients.[1][3]
Brookline Capital Markets was co-founded by three former Wall Street colleagues, each with over 25 years of experience in capital markets, advisory, and equity sales at top financial institutions.[1][4] In its early years, the firm operated as a life sciences-focused family office, making successful early-stage investments that honed its sector DNA.[4] It evolved into a full investment banking platform, launching public capital markets capabilities in 2017 through FINRA member Arcadia Securities, LLC, expanding to private and public financing for healthcare innovators, SPACs, and growth enterprises.[1][4]
This progression reflects a shift from direct investing to comprehensive advisory and execution services, building on founders' Wall Street roots to establish a reputation for repeat client relationships and high-volume deal flow.[1][4]
Brookline rides the wave of healthcare innovation, particularly in life sciences and medtech, where demand for specialized financing persists amid volatile public markets and extended private timelines.[1][3] Its timing aligns with a resurgence in biotech IPOs and SPAC activity post-2017, capitalizing on sector tailwinds like diagnostics advancements and aging populations driving medtech growth.[1] Market forces favoring it include fragmented family office capital seeking high-upside healthcare deals and regulatory shifts enabling faster clinical-to-market paths.[2][3]
The firm influences the ecosystem by bridging private-to-public transitions for startups, enabling scale for cutting-edge companies and sustaining Wall Street's boutique presence in underserved healthcare niches.[1][4]
Brookline is poised to expand its deal volume amid recovering equity markets, leveraging its healthcare focus for more pre-IPO mandates and crossovers into AI-driven diagnostics.[1][5] Trends like personalized medicine and global family office inflows will shape its trajectory, potentially doubling private raises as biotech funding normalizes.[2] Its influence may evolve toward deeper tech-health intersections, solidifying its role as a go-to partner for innovative firms navigating capital scarcity—echoing its founding promise of client longevity in a dynamic sector.[1][3]
